v3.26.1
CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS - USD ($)
$ in Millions
3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Income Statement [Abstract]        
Sales $ 16,607 $ 15,806 $ 32,893 $ 31,335
Costs, Expenses and Other        
Cost of sales 4,395 3,557 8,590 6,976
Selling, general and administrative 2,904 2,649 5,604 5,202
Research and development 9,741 4,048 22,333 7,669
Restructuring costs 151 560 346 629
Other (income) expense, net 99 (7) 237 (43)
Total Costs, Expenses and Other 17,290 10,807 37,110 20,433
(Loss) Income Before Taxes (683) 4,999 (4,217) 10,902
Income Tax Provision 654 571 1,363 1,388
Net (Loss) Income (1,337) 4,428 (5,580) 9,514
Less: Net (Loss) Income Attributable to Noncontrolling Interests (2) 1 (5) 8
Net (Loss) Income Attributable to Merck & Co., Inc. $ (1,335) $ 4,427 $ (5,575) $ 9,506
Basic (Loss) Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share) $ (0.54) $ 1.76 $ (2.26) $ 3.78
(Loss) Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share) $ (0.54) $ 1.76 $ (2.26) $ 3.77